leonardo drs - DRS

DRS

Close Chg Chg %
46.32 -0.03 -0.06%

Open Market

46.29

-0.03 (0.06%)

Volume: 449.28K

Last Updated:

Mar 26, 2026, 1:17 PM EDT

Company Overview: leonardo drs - DRS

DRS Key Data

Open

$45.88

Day Range

45.47 - 46.34

52 Week Range

28.17 - 49.31

Market Cap

$1.47B

Shares Outstanding

145.00M

Public Float

75.45M

Beta

N/A

Rev. Per Employee

N/A

P/E Ratio

3.52

EPS

N/A

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.21M

 

DRS Performance

1 Week
 
5.71%
 
1 Month
 
6.75%
 
3 Months
 
35.12%
 
1 Year
 
41.09%
 
5 Years
 
313.57%
 

DRS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About leonardo drs - DRS

Leonardo DRS, Inc. engages in the provision of defense products and technologies. It develops and manufactures defense products for the U.S. military, intelligence agencies and allies around the world. Its broad technology portfolio focuses on advanced sensing, network computing, force protection, and electrical power and propulsion, as well as a range of key defense priorities. The company operates through the Advanced Sensors and Computing and Integrated Mission Systems segments. The Advanced Sensors and Computing segment have been aligned to push towards a more autonomous future. It consists of six business units, which include Airborne & Intelligence Systems, Daylight Solutions, DRS RADA Technologies, Electro-Optical & Infrared Systems, Land Electronics, and Naval Electronics. The Integrated Mission Systems segment consists of both a ground vehicle integrator and naval power and propulsion system provider. The company was founded by Leonard Newman and David E. Gross in 1969 and is headquartered in Arlington, VA.

DRS At a Glance

Leonardo DRS, Inc.
2345 Crystal Drive
Arlington, Virginia 22202
Phone 1-703-416-8000 Revenue 3.65B
Industry Aerospace & Defense Net Income 278.00M
Sector Electronic Technology 2025 Sales Growth 12.801%
Fiscal Year-end 12 / 2026 Employees 7,300
View SEC Filings

DRS Valuation

P/E Current 3.518
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 32.95
Price to Sales Ratio 2.511
Price to Book Ratio 3.319
Price to Cash Flow Ratio 25.03
Enterprise Value to EBITDA 20.278
Enterprise Value to Sales 2.462
Total Debt to Enterprise Value 0.052

DRS Efficiency

Revenue/Employee 499,726.027
Income Per Employee 38,082.192
Receivables Turnover 2.884
Total Asset Turnover 0.814

DRS Liquidity

Current Ratio 1.89
Quick Ratio 1.604
Cash Ratio 0.526

DRS Profitability

Gross Margin 23.218
Operating Margin 9.594
Pretax Margin 9.211
Net Margin 7.621
Return on Assets 6.205
Return on Equity 10.516
Return on Total Capital 8.688
Return on Invested Capital 9.101

DRS Capital Structure

Total Debt to Total Equity 17.216
Total Debt to Total Capital 14.688
Total Debt to Total Assets 10.18
Long-Term Debt to Equity 15.238
Long-Term Debt to Total Capital 13.00
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Leonardo Drs - DRS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.69B 2.83B 3.23B 3.65B
Sales Growth
-6.46% +4.94% +14.44% +12.80%
Cost of Goods Sold (COGS) incl D&A
2.13B 2.20B 2.52B 2.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
65.00M 85.00M 91.00M 93.00M
Depreciation
55.00M 63.00M 69.00M 71.00M
Amortization of Intangibles
10.00M 22.00M 22.00M 22.00M
COGS Growth
-9.10% +3.38% +14.55% +11.15%
Gross Income
565.00M 626.00M 714.00M 847.00M
Gross Income Growth
+5.02% +10.80% +14.06% +18.63%
Gross Profit Margin
+20.98% +22.15% +22.08% +23.22%
2022 2023 2024 2025 5-year trend
SG&A Expense
314.00M 377.00M 414.00M 497.00M
Research & Development
- - - -
-
Other SG&A
314.00M 377.00M 414.00M 497.00M
SGA Growth
+7.17% +20.06% +9.81% +20.05%
Other Operating Expense
- - (2.00M) (1.00M)
-
Unusual Expense
46.00M 18.00M 8.00M 2.00M
EBIT after Unusual Expense
207.00M 231.00M 293.00M 348.00M
Non Operating Income/Expense
352.00M (3.00M) (8.00M) (4.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
34.00M 36.00M 21.00M 8.00M
Interest Expense Growth
-2.86% +5.88% -41.67% -61.90%
Gross Interest Expense
34.00M 36.00M 21.00M 8.00M
Interest Capitalized
- - - -
-
Pretax Income
525.00M 192.00M 264.00M 336.00M
Pretax Income Growth
+162.50% -63.43% +37.50% +27.27%
Pretax Margin
+19.49% +6.79% +8.16% +9.21%
Income Tax
120.00M 24.00M 51.00M 58.00M
Income Tax - Current - Domestic
117.00M 75.00M 26.00M 25.00M
Income Tax - Current - Foreign
- 1.00M 2.00M 5.00M
Income Tax - Deferred - Domestic
(1.00M) (51.00M) 20.00M 31.00M
Income Tax - Deferred - Foreign
4.00M (1.00M) 3.00M (3.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
405.00M 168.00M 213.00M 278.00M
Minority Interest Expense
- - - -
-
Net Income
405.00M 168.00M 213.00M 278.00M
Net Income Growth
+162.99% -58.52% +26.79% +30.52%
Net Margin Growth
+15.04% +5.94% +6.59% +7.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
405.00M 168.00M 213.00M 278.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
405.00M 168.00M 213.00M 278.00M
EPS (Basic)
1.8837 0.6437 0.8077 1.0455
EPS (Basic) Growth
+77.36% -65.83% +25.48% +29.44%
Basic Shares Outstanding
215.00M 261.00M 263.70M 265.90M
EPS (Diluted)
1.8837 0.6364 0.7957 1.0346
EPS (Diluted) Growth
+77.36% -66.22% +25.03% +30.02%
Diluted Shares Outstanding
215.00M 264.00M 267.70M 268.70M
EBITDA
318.00M 334.00M 392.00M 443.00M
EBITDA Growth
+8.16% +5.03% +17.37% +13.01%
EBITDA Margin
+11.81% +11.82% +12.12% +12.14%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 51.00
Number of Ratings 12 Current Quarters Estimate 0.206
FY Report Date 03 / 2026 Current Year's Estimate 1.255
Last Quarter’s Earnings 0.42 Median PE on CY Estimate N/A
Year Ago Earnings 1.15 Next Fiscal Year Estimate 1.408
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 10 10 9
Mean Estimate 0.21 0.26 1.26 1.41
High Estimates 0.23 0.31 1.30 1.51
Low Estimate 0.19 0.20 1.20 1.35
Coefficient of Variance 5.39 12.13 2.52 4.43

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 7 8
OVERWEIGHT 1 1 1
HOLD 3 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Leonardo Drs - DRS

Date Name Shares Transaction Value
Mar 6, 2026 George W. Casey Director 28,820 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.14 per share 1,300,934.80
Dec 3, 2025 Michael D. Dippold EVP and CFO 53,540 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.74 per share 1,806,439.60
Dec 3, 2025 Mark A. Dorfman EVP, GC and Secretary 35,360 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.74 per share 1,193,046.40
Apr 7, 2025 Sally A. Wallace EVP, Business Operations 9,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 Pamela J. Morrow SVP and Controller 5,705 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 John A. Baylouny EVP and COO 18,026 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 7, 2025 William J. Lynn Chief Executive Officer; Director 68,605 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Mark A. Dorfman EVP, GC and Secretary 7,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 William J. Lynn Chief Executive Officer; Director 46,361 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Pamela J. Morrow SVP and Controller 8,273 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 William J. Lynn Chief Executive Officer; Director 383,291 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 William J. Lynn Chief Executive Officer; Director 351,538 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.87 per share 11,555,054.06
Apr 4, 2025 Mark A. Dorfman EVP, GC and Secretary 9,542 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Mark A. Dorfman EVP, GC and Secretary 52,001 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.87 per share 1,709,272.87
Apr 4, 2025 Mark A. Dorfman EVP, GC and Secretary 54,305 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Mark A. Dorfman EVP, GC and Secretary 49,535 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.87 per share 1,628,215.45
Apr 4, 2025 John A. Baylouny EVP and COO 16,652 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 John A. Baylouny EVP and COO 12,627 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 John A. Baylouny EVP and COO 140,812 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.87 per share 4,628,490.44
Apr 4, 2025 John A. Baylouny EVP and COO 144,567 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Leonardo Drs in the News